QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$48.30
+1.0%
$51.26
$47.58
$70.93
$97.89B0.3915.78 million shs10.91 million shs
GSK plc stock logo
GSK
GSK
$39.27
-0.8%
$41.99
$33.33
$43.84
$81.38B0.643.50 million shs2.16 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$745.95
-0.6%
$764.03
$367.35
$800.78
$708.77B0.343.07 million shs1.70 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-0.91%-4.88%-7.29%-4.49%-31.90%
GSK plc stock logo
GSK
GSK
-0.86%-2.67%-6.05%+0.15%+7.67%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.58%-1.36%-1.55%+20.46%+102.99%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.9335 of 5 stars
3.15.03.34.03.11.72.5
GSK plc stock logo
GSK
GSK
2.639 of 5 stars
0.03.03.30.02.60.02.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8162 of 5 stars
2.44.02.54.02.52.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$61.1826.66% Upside
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-2.40% Downside

Current Analyst Ratings

Latest GSK, LLY, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
3/22/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$850.00
3/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$775.00 ➝ $850.00
3/11/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/4/2024
GSK plc stock logo
GSK
GSK
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B2.18$12.48 per share3.87$14.49 per share3.33
GSK plc stock logo
GSK
GSK
$37.71B2.16$5.09 per share7.71$7.74 per share5.07
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.77$7.62 per share97.92$11.44 per share65.21

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B$3.8612.516.951.4917.83%50.95%16.67%4/25/2024 (Confirmed)
GSK plc stock logo
GSK
GSK
$6.13B$3.0113.058.841.8316.24%51.45%10.57%5/1/2024 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80128.6140.301.6315.36%51.22%9.94%4/30/2024 (Confirmed)

Latest GSK, LLY, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
GSK plc stock logo
GSK
GSK
$0.95N/A-$0.95N/AN/AN/A
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/25/2024N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.4730N/A+$4.4730N/AN/AN/A  
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55$1.70+$0.15$2.53$11.19 billion$11.48 billion    
1/31/2024Q4 2023
GSK plc stock logo
GSK
GSK
$0.76$0.72-$0.04$1.23$9.79 billion$10.00 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.404.97%+8.20%62.18%N/A
GSK plc stock logo
GSK
GSK
$1.594.05%-18.20%52.82%1 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.70%+15.15%89.66%10 Years

Latest GSK, LLY, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
2/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.35643.4%2/22/20242/23/20244/11/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
1.24
1.43
1.31
GSK plc stock logo
GSK
GSK
1.19
0.88
0.62
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
GSK plc stock logo
GSK
GSK
15.74%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
GSK plc stock logo
GSK
GSK
10.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.02 billionOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable

GSK, LLY, and BMY Headlines

SourceHeadline
Eli Lilly and Company (NYSE:LLY) Shares Sold by Calamos Advisors LLCEli Lilly and Company (NYSE:LLY) Shares Sold by Calamos Advisors LLC
marketbeat.com - April 18 at 4:49 PM
Eli Lilly and Company (NYSE:LLY)  Shares Down 0.1% Eli Lilly and Company (NYSE:LLY) Shares Down 0.1%
marketbeat.com - April 18 at 2:47 PM
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)
markets.businessinsider.com - April 18 at 2:14 PM
As Zepbound shortage grows, Eli Lilly says no immediate end is in sightAs Zepbound shortage grows, Eli Lilly says no immediate end is in sight
msn.com - April 18 at 2:14 PM
Indias Biocon developing its own version of Wegovy, clinical trial likely next yearIndia's Biocon developing its own version of Wegovy, clinical trial likely next year
finance.yahoo.com - April 18 at 2:14 PM
Big pharma: cautious optimism ahead of earnings season - analystsBig pharma: cautious optimism ahead of earnings season - analysts
proactiveinvestors.com - April 18 at 11:35 AM
Eli Lillys (LLY) Tirzepatide Meets Goals in Sleep Apnea StudiesEli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
zacks.com - April 18 at 9:55 AM
Q1 2025 EPS Estimates for Eli Lilly and Company Reduced by Zacks Research (NYSE:LLY)Q1 2025 EPS Estimates for Eli Lilly and Company Reduced by Zacks Research (NYSE:LLY)
marketbeat.com - April 18 at 6:31 AM
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
fool.com - April 18 at 5:10 AM
Eli Lillys Weight Loss Drug Zepbound Shows Promise In Reducing Sleep ApneaEli Lilly's Weight Loss Drug Zepbound Shows Promise In Reducing Sleep Apnea
markets.businessinsider.com - April 18 at 12:39 AM
Eli Lilly’s weight-loss drug Zepbound might help cure your sleep apneaEli Lilly’s weight-loss drug Zepbound might help cure your sleep apnea
fastcompany.com - April 18 at 12:39 AM
Even more doses of Eli Lillys Zepbound and Mounjaro are officially in a shortage, FDA saysEven more doses of Eli Lilly's Zepbound and Mounjaro are officially in a shortage, FDA says
msn.com - April 18 at 12:39 AM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Daiwa Securities Group Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)Daiwa Securities Group Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 17 at 6:50 PM
These Stocks Are Moving the Most Today: United Airlines, Travelers, J.B. Hunt, Eli Lilly, ASML, Alcoa, and MoreThese Stocks Are Moving the Most Today: United Airlines, Travelers, J.B. Hunt, Eli Lilly, ASML, Alcoa, and More
msn.com - April 17 at 2:39 PM
Eli Lilly and Company (NYSE:LLY)  Shares Down 0.5% Eli Lilly and Company (NYSE:LLY) Shares Down 0.5%
marketbeat.com - April 17 at 12:42 PM
Eli Lillys Weight-Loss Treatment Found To Help Those With Sleep ApneaEli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea
investopedia.com - April 17 at 12:15 PM
Wall Street Lunch: Lilly In LimelightWall Street Lunch: Lilly In Limelight
seekingalpha.com - April 17 at 11:27 AM
Most doses of Eli Lillys Zepbound, Mounjaro in short supply through June, FDA saysMost doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
cnbc.com - April 17 at 11:23 AM
Eli Lilly Stock Pops on Drug Efficacy for Sleep ApneaEli Lilly Stock Pops on Drug Efficacy for Sleep Apnea
schaeffersresearch.com - April 17 at 10:40 AM
Most doses of Lillys Mounjaro and Zepbound in limited availability, US FDA saysMost doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says
reuters.com - April 17 at 9:38 AM
Eli Lilly, plaintiffs agree to scrap $13.5M insulin pricing settlementEli Lilly, plaintiffs agree to scrap $13.5M insulin pricing settlement
fiercepharma.com - April 17 at 9:38 AM
Another perk of weight-loss drugs? Eli Lillys Zepbound may alleviate sleep apnea, tooAnother perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too
msn.com - April 17 at 9:38 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.